

Jennifer Le

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5598342/publications.pdf>

Version: 2024-02-01

43
papers

2,093
citations

279487

23
h-index

253896

43
g-index

44
all docs

44
docs citations

44
times ranked

2139
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation of Vancomycin Therapeutic Monitoring Guidelines: Focus on Bayesian Estimation Tools in Neonatal and Pediatric Patients. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 241-252.	1.0	8
2	Vancomycin therapeutic monitoring by measured trough concentration versus Bayesian-derived area under the curve in critically ill patients with cancer. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00912.	1.1	3
3	Ampicillin dosing in premature infants for early-onset sepsis: exposure-driven efficacy, safety, and stewardship. <i>Journal of Perinatology</i> , 2022, 42, 959-964.	0.9	4
4	Prolonged Post-Discontinuation Antibiotic Exposure in Very Low Birth Weight Neonates at Risk for Early-Onset Sepsis. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 615-621.	0.6	7
5	Antimicrobial prescribing for treatment of serious infections caused by <i>Staphylococcus aureus</i> and methicillin-resistant <i>Staphylococcus aureus</i> in pediatrics: an expert review. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1107-1116.	2.0	5
6	<i>Clostridium difficile</i> : Diagnosis and the Consequence of Over Diagnosis. <i>Infectious Diseases and Therapy</i> , 2021, 10, 687-697.	1.8	38
7	Optimizing Aminoglycoside Dosing Regimens for Critically Ill Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	6
8	Comment on: AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2486-2488.	1.3	3
9	Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 162-169.	1.3	9
10	Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Clinical Infectious Diseases</i> , 2020, 71, 1361-1364.	2.9	142
11	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 281-284.	0.6	33
12	Paradoxical Antibiotic Effect of Ampicillin. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 725-729.	1.1	5
13	Questions on Vancomycin Dosing. <i>Clinical Infectious Diseases</i> , 2020, 73, e1777-e1778.	2.9	1
14	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1195-1216.	1.6	28
15	Emerging Viral and Bacterial Infections: Within an Era of Opioid Epidemic. <i>Infectious Diseases and Therapy</i> , 2020, 9, 737-755.	1.8	1
16	Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus</i> infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>American Journal of Infectious Diseases</i> , 2020, 71, 1361-1364.	0.5	640
17	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2020, 40, 363-367.	1.2	56
18	Use of Simulation Strategies to Predict Subtherapeutic Meropenem Exposure Caused by Augmented Renal Clearance in Critically Ill Pediatric Patients With Sepsis. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2020, 25, 413-422.	0.3	11

#	ARTICLE	IF	CITATIONS
19	Cost-effective analysis of low- versus high-dose colistin in the treatment of multi-drug resistant pneumonia in Saudi Arabia. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 1-2.	1.0	1
20	Antimicrobial Susceptibility of <i>Streptococcus pneumoniae</i> from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016). <i>Open Forum Infectious Diseases</i> , 2019, 6, S14-S23.	0.4	56
21	Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 103-108.	1.0	9
22	Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs. <i>Journal of Clinical Pharmacology</i> , 2018, 58, S108-S122.	1.0	37
23	Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing. <i>Pharmacotherapy</i> , 2017, 37, 361-378.	1.2	26
24	Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2017, 52, 1424-1434.	1.0	15
25	Case report of transient <i>mcr-1</i> -harboring <i>Escherichia coli</i> with concurrent <i>Staphylococcus aureus</i> bacteremia in Long Beach, California. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 89, 303-304.	0.8	6
26	Augmented Renal Clearance Using Population-Based Pharmacokinetic Modeling in Critically Ill Pediatric Patients*. <i>Pediatric Critical Care Medicine</i> , 2017, 18, e388-e394.	0.2	56
27	Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 448-453.	0.5	27
28	Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, e109-e116.	0.6	82
29	Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study. <i>Clinical Therapeutics</i> , 2015, 37, 1340-1351.	1.1	24
30	A Formal Mentorship Program for Faculty Development. <i>American Journal of Pharmaceutical Education</i> , 2014, 78, 100.	0.7	56
31	Characterization of the Population Pharmacokinetics of Ampicillin in Neonates Using an Opportunistic Study Design. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3013-3020.	1.4	62
32	Vancomycin Monitoring in Children Using Bayesian Estimation. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 510-518.	1.0	35
33	Population-Based Pharmacokinetic Modeling of Vancomycin in Children with Renal Insufficiency. <i>Journal of Pharmacology & Clinical Toxicology</i> , 2014, 2, 1017-1026.	0.5	13
34	Time to Initiation of Antifungal Therapy for Neonatal Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2550-2555.	1.4	5
35	Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e155-e163.	1.1	199
36	Incidence and Risk Factors Influencing the Development of Vancomycin Nephrotoxicity in Children. <i>Journal of Pediatrics</i> , 2011, 158, 422-426.	0.9	161

#	ARTICLE	IF	CITATIONS
37	Case-control study of risk factors and outcomes associated with neonatal candidiasis. <i>Journal of Neonatal-Perinatal Medicine</i> , 2011, 4, 39-43.	0.4	1
38	In Vitro Activity of Carbapenems Alone and in Combination With Amikacin Against KPC-Producing <i>Klebsiella Pneumoniae</i> . <i>Journal of Clinical Medicine Research</i> , 2011, 3, 106-10.	0.6	28
39	Aerosolized Delivery of Antifungal Agents. <i>Current Fungal Infection Reports</i> , 2010, 4, 96-102.	0.9	32
40	Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria. <i>Pharmacotherapy</i> , 2010, 30, 562-584.	1.2	77
41	Clonal Dissemination of <i>Klebsiella pneumoniae</i> Carbapenemase KPC-3 in Long Beach, California. <i>Journal of Clinical Microbiology</i> , 2010, 48, 623-625.	1.8	15
42	Complications Associated With Outpatient Parenteral Antibiotic Therapy in Children. <i>Clinical Pediatrics</i> , 2010, 49, 1038-1043.	0.4	27
43	Treatment of Meningitis Caused by Vancomycin-Resistant <i>Enterococcus faecium</i> : High-Dose and Combination Daptomycin Therapy. <i>Annals of Pharmacotherapy</i> , 2010, 44, 2001-2006.	0.9	43